Perea F Javier, Magaña María Teresa, Cobián José G, Sánchez-López J Yoaly, Chávez María L, Zamudio Guadalupe, Esparza María A, López-Guido Beatriz, Ibarra Bertha
División de Genética, Centro de Investigación Biomédica de Occidente, CMNO, IMSS, Guadalajara, Jalisco, Mexico.
Blood Cells Mol Dis. 2004 Sep-Oct;33(2):150-2. doi: 10.1016/j.bcmd.2004.06.001.
Beta-thalassemia (beta-thal) is present in 59% and 75% of patients with abnormal hemoglobin disorders in northwestern and central Mexico, respectively. In our Research Center, up until 1997, we reported the presence of 13 beta-thal alleles in 26 unrelated chromosomes (-28A>C; -87C>T; MET1VAL; IVS1, G>A, +1; IVS1, G>A, +5; IVS1, G>C, +5; IVS1, G>A, +110; IVS2, C>G, +745; GLU6FS; VAL11FS; GLN39TER; HBD/HBB 104 kb del; and HBD87/HBB116 fusion). Since then, 57 more beta-thal chromosomes have been identified by the amplification-refractory mutation system (ARMS) and DNA sequencing from 54 individuals with beta-thalassemia (seven compound heterozygotes, three with two beta-thal alleles, three with beta-thal and HbS, and one with beta-thal and HbD; and 47 beta-thal heterozygotes). Nine of the previously observed alleles were found, together with three new alleles: IVS2, G>A, +1; LYS17TER; and 4-bp del, 41/42CTTT. Moreover, a novel mutation was observed, HIS77FS, bringing to a total of 17 beta-thal alleles identified in our population. Six alleles constitute 78.3% of the observed alleles: five Mediterranean alleles (GLN39TER; IVS1, G>A, +1; IVS1, G>A, +110; HBD/HBB 104 kb del; and IVS1, G>A, +5) and one common in the Kurdish population (-28A>C). We note especially the presence in these families of -28A>C and VAL11FS, both of which have previously been considered private alleles. The observed spectrum of mutations is characteristic of populations with low frequencies of thalassemias. Because thalassemia is not a rare disease in Mexico, we emphasize its necessary consideration in the differential diagnosis of microcytic hypochromic anemia.
β地中海贫血(β-地贫)在墨西哥西北部和中部血红蛋白异常疾病患者中分别占59%和75%。在我们的研究中心,截至1997年,我们报告在26条不相关染色体中存在13个β-地贫等位基因(-28A>C;-87C>T;MET1VAL;IVS1,G>A,+1;IVS1,G>A,+5;IVS1,G>C,+5;IVS1,G>A,+110;IVS2,C>G,+745;GLU6FS;VAL11FS;GLN39TER;HBD/HBB 104 kb缺失;以及HBD87/HBB116融合)。从那时起,通过扩增阻滞突变系统(ARMS)和DNA测序,又在54例β地中海贫血患者(7例复合杂合子、3例携带两个β-地贫等位基因、3例携带β-地贫和HbS、1例携带β-地贫和HbD;以及47例β-地贫杂合子)中鉴定出57条更多的β-地贫染色体。发现了9个先前观察到的等位基因,以及3个新等位基因:IVS2,G>A,+1;LYS17TER;以及4-bp缺失,41/42CTTT。此外,还观察到一个新突变,HIS77FS,使我们人群中鉴定出的β-地贫等位基因总数达到17个。6个等位基因占观察到的等位基因的78.3%:5个地中海等位基因(GLN39TER;IVS1,G>A,+1;IVS1,G>A,+110;HBD/HBB 104 kb缺失;以及IVS1,G>A,+5)和1个在库尔德人群中常见的等位基因(-28A>C)。我们特别注意到这些家族中存在-28A>C和VAL11FS,这两个等位基因以前都被认为是私有等位基因。观察到的突变谱是地中海贫血低发人群的特征。由于地中海贫血在墨西哥并非罕见疾病,我们强调在小细胞低色素性贫血的鉴别诊断中必须考虑到它。